The interview schedule was developed through discussion with healthcare professionals including a clinician working in a tier 3 obesity service, a diabetes physician, and a psychiatrist specialising in diabetes and mental health, as well as a member of the public with lived experience of taking a GLP-1 receptor agonist (see supplementary material p3). Here, GLP1R is linked to obesity disorder.